--- title: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus nct_id: NCT02000700 overall_status: COMPLETED phase: PHASE1 sponsor: Janssen Research & Development, LLC study_type: INTERVENTIONAL primary_condition: Diabetes Mellitus, Type 2 countries: United States, Brazil canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02000700.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02000700" ct_last_update_post_date: 2017-03-03 last_seen_at: "2026-05-12T07:19:46.985Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus **Official Title:** Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin **NCT ID:** [NCT02000700](https://clinicaltrials.gov/study/NCT02000700) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE1 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 17 - **Lead Sponsor:** Janssen Research & Development, LLC - **Conditions:** Diabetes Mellitus, Type 2 - **Start Date:** 2014-03 - **Completion Date:** 2016-04 - **CT.gov Last Update:** 2017-03-03 ## Brief Summary The purpose of this study is to evaluate the pharmacokinetics (blood levels) and pharmacodynamics (the action or effects a drug has on the body) of canagliflozin in children and adolescents with type 2 diabetes mellitus aged 10 to 17 years (inclusive). Other purposes are to investigate safety and assess the ease of swallowing the tablets. ## Detailed Description The participants who meet the eligibility criteria, will receive a single dose of placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) and this will be followed by baseline 24 hour pharmacodynamic assessments. On the next morning participants will receive the first canagliflozin dose and will be discharged home to continue canagliflozin treatment for 13 additional days. There will be 2 treatment groups (8 participants in each): the first group will receive canagliflozin 100 mg daily, the second group will receive either canagliflozin 300 mg or canagliflozin 50 mg daily. The canagliflozin dose for the second treatment group will be determined after the sponsor has evaluated the results from the first 5 participants. On day 14 of treatment the participants will be admitted again for 24 hour pharmacokinetic and pharmacodynamics assessments. The participants will continue to take their normal dose and schedule of metformin during the entire study. The total duration of the study is approximately 50 days. ## Eligibility - **Minimum age:** 10 Years - **Maximum age:** 17 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Diagnosed with Type 2 Diabetes Mellitus * Be on a stable regimen of metformin immediate release (IR) monotherapy of at least 1,000 mg/day for at least 8 weeks before screening * Able to swallow whole tablets * Absence of pancreatic autoimmunity * Participants and their caregivers must agree to perform the fasting fingerstick glucose self-monitoring during the study Exclusion Criteria: * History of Type 1 diabetes mellitus * History of maturity onset diabetes of the young (MODY) and any secondary form of diabetes * Current clinically significant medical illness e.g., significant pulmonary disease, renal or hepatic insufficiency, uncontrolled thyroid disease * Systolic or diastolic blood pressure outside the range considered normal for the participant sex, age and height * For females, participants will be excluded if pregnant ``` ## Arms - **Canagliflozin (Dose Group 1)** (EXPERIMENTAL) — Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days. - **Canagliflozin (Dose Group 2)** (EXPERIMENTAL) — Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days. ## Interventions - **Canagliflozin 100 mg** (DRUG) — One 100-mg tablet of canagliflozin orally administered daily for 14 days. - **Canagliflozin 50 mg** (DRUG) — One 50-mg tablet of canagliflozin orally administered daily for 14 days. - **Canagliflozin 300 mg** (DRUG) — One 300-mg tablet of canagliflozin orally administered daily for 14 days. - **Placebo** (DRUG) — One matching placebo tablet orally administered at baseline phase. ## Primary Outcomes - **Plasma concentrations of canagliflozin following multiple oral doses of canagliflozin** _(time frame: From Days 14 to 17)_ — Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body. ## Secondary Outcomes - **Plasma glucose concentration following multiple oral doses of canagliflozin** _(time frame: From Days -1 to 1, and from Days 14 to 15)_ - **Urine glucose excretion following multiple oral doses of canagliflozin** _(time frame: From Days -1 to 1, and from Days 14 to 15)_ - **Renal threshold for glucose excretion following multiple oral doses of canagliflozin** _(time frame: From Days -1 to 1, and from Days 14 to 15)_ - **Acceptability of the canagliflozin tablet** _(time frame: Day 14)_ - **Number of participants with adverse events as a measure of safety and tolerability** _(time frame: Approximately 50 days)_ ## Locations (17) - Little Rock, Arkansas, United States - Los Angeles, California, United States - Aurora, Colorado, United States - New Haven, Connecticut, United States - Jacksonville, Florida, United States - Indianapolis, Indiana, United States - Lenexa, Kansas, United States - Baltimore, Maryland, United States - Kansas City, Missouri, United States - Toledo, Ohio, United States - Pittsburgh, Pennsylvania, United States - Houston, Texas, United States - Salt Lake City, Utah, United States - Campinas, Brazil - Curitiba, Brazil - Ribeirão Preto, Brazil - São Paulo, Brazil ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.|little rock|arkansas|united states` — added _(2026-05-12)_ - `locations.|los angeles|california|united states` — added _(2026-05-12)_ - `locations.|aurora|colorado|united states` — added _(2026-05-12)_ - `locations.|new haven|connecticut|united states` — added _(2026-05-12)_ - `locations.|jacksonville|florida|united states` — added _(2026-05-12)_ - `locations.|indianapolis|indiana|united states` — added _(2026-05-12)_ - `locations.|lenexa|kansas|united states` — added _(2026-05-12)_ - `locations.|baltimore|maryland|united states` — added _(2026-05-12)_ - `locations.|kansas city|missouri|united states` — added _(2026-05-12)_ - `locations.|toledo|ohio|united states` — added _(2026-05-12)_ - `locations.|pittsburgh|pennsylvania|united states` — added _(2026-05-12)_ - `locations.|houston|texas|united states` — added _(2026-05-12)_ - `locations.|salt lake city|utah|united states` — added _(2026-05-12)_ - `locations.|campinas||brazil` — added _(2026-05-12)_ - `locations.|curitiba||brazil` — added _(2026-05-12)_ - `locations.|ribeirão preto||brazil` — added _(2026-05-12)_ - `locations.|são paulo||brazil` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02000700.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02000700* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*